TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• TuHURA Biosciences reported quarterly EPS of $(0.14), beating analysts’ consensus estimate of $(0.15) by $0.01.
• Shares rose 7.4% to $2.47 in midday trading, giving the company a market capitalization of approximately $157.3 million.
• Analyst sentiment remains mixed but leans positive: five analysts rate the stock a Buy and one rates it a Sell, producing a consensus “Moderate Buy” rating and a $9.00 price target.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01, FiscalAI reports.

TuHURA Biosciences Trading Up 7.4%

Shares of NASDAQ HURA traded up $0.17 during midday trading on Friday, reaching $2.47. The company's stock had a trading volume of 317,089 shares, compared to its average volume of 1,079,055. The company has a market cap of $157.30 million, a price-to-earnings ratio of -4.05 and a beta of -0.01. TuHURA Biosciences has a one year low of $0.41 and a one year high of $3.43. The company has a 50 day moving average price of $2.27 and a 200 day moving average price of $2.00.

Wall Street Analyst Weigh In

HURA has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday, May 31st. Citigroup initiated coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an "outperform" rating for the company. Citizens Jmp initiated coverage on TuHURA Biosciences in a report on Monday, April 27th. They set a "market outperform" rating and a $9.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TuHURA Biosciences in a research note on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in HURA. Virtu Financial LLC acquired a new stake in shares of TuHURA Biosciences in the third quarter worth $26,000. JPMorgan Chase & Co. purchased a new position in TuHURA Biosciences in the second quarter valued at about $27,000. Invesco Ltd. acquired a new position in TuHURA Biosciences in the 2nd quarter worth about $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TuHURA Biosciences during the 2nd quarter valued at about $31,000. Finally, Bank of America Corp DE bought a new stake in shares of TuHURA Biosciences in the 4th quarter valued at approximately $59,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.